The Lynx Group

Value-Based Care

Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit. The discussion was moderated by Clifford Goodman, PhD, Senior Vice President, Comparative Effectiveness Research, the Lewin Group.
Read Article

Value-based or alternative payment models have yet to deliver the cost-savings in oncology hoped for when these models were proposed, said experts at the September 2020 National Comprehensive Cancer Network Oncology Policy Summit during a panel discussion on best practices for value-based agreements.
Read Article

When ASCO President Howard A. Burris III, MD, FACP, FASCO, chose the theme for the 2020 annual meeting—“Unite and Conquer: Accelerating Progress Together”—early last year, he never imagined that it would take on new meaning just 12 months later.
Read Article

As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists.
Read Article

Cemiplimab-rwlc (Libtayo), a PD-1 inhibitor, has transformed the treatment of advanced ­cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients.
Read Article


An analysis of the Value Framework of the American Society of Clinical Oncology (ASCO) shows that the Net Health Benefit score of cancer drugs continues to evolve over time after their FDA approval, based on data presented at the ASCO 2020 virtual annual meeting.
Read Article

Two studies presented at the 2020 American Association for Cancer Research virtual annual meeting confirm the value of different liquid biopsies in the early detection of different types of cancer.
Read Article

The first “off-the-shelf” chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) who received treatment with the universal CAR T-cell therapy currently labeled GC027.
Read Article

Every infusion center needs to understand what resources it has (or will have) available at any given time during any particular day—whether it is open chairs, treating registered nurses, or pharmacy staff. This knowledge is vital to decision-making that affects the patient experience, as well as staffing decisions, operations, and, ultimately, revenue.
Read Article

Page 1 of 11

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: